Comparative Efficacy of Tetracyclines Against Isolates of Complex

Overview

Journal IJTLD Open

Date 2025 Feb 17

PMID 39959406

Authors

S Singh

G D Boorgula

A Shrivastava

T Gumbo

S Srivastava

Affiliations

Soon will be listed here.

References

Singh S, Boorgula G, Aryal S, Philley J, Gumbo T, Srivastava S . Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so far. J Antimicrob Chemother. 2023; 79(1):96-99. PMC: 11032240. DOI: 10.1093/jac/dkad352. View

Kwak N, Park J, Kim E, Lee C, Han S, Yim J . Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis. Clin Infect Dis. 2017; 65(7):1077-1084. DOI: 10.1093/cid/cix517. View

Daley C, Iaccarino J, Lange C, Cambau E, Wallace R, Andrejak C . Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020; 71(4):905-913. PMC: 7768745. DOI: 10.1093/cid/ciaa1125. View

Kamii Y, Nagai H, Kawashima M, Matsuki M, Nagoshi S, Sato A . Adverse reactions associated with long-term drug administration in complex lung disease. Int J Tuberc Lung Dis. 2019; 22(12):1505-1510. DOI: 10.5588/ijtld.18.0171. View

Roussel G, Igual J . Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. Int J Tuberc Lung Dis. 1998; 2(6):462-70. View

Samara E, Moriarty T, Decosterd L, Richards R, Gautier E, Wahl P . Antibiotic stability over six weeks in aqueous solution at body temperature with and without heat treatment that mimics the curing of bone cement. Bone Joint Res. 2017; 6(5):296-306. PMC: 5457644. DOI: 10.1302/2046-3758.65.BJR-2017-0276.R1. View

Chopra I, Roberts M . Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001; 65(2):232-60 ; second page, table of contents. PMC: 99026. DOI: 10.1128/MMBR.65.2.232-260.2001. View

Chapagain M, Pasipanodya J, Athale S, Bernal C, Trammell R, Howe D . Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses. J Antimicrob Chemother. 2022; 77(6):1694-1705. PMC: 9155607. DOI: 10.1093/jac/dkac068. View

Boorgula G, Gumbo T, Singh S, McShane P, Philley J, Srivastava S . Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation. Tuberculosis (Edinb). 2024; 147:102519. PMC: 11345947. DOI: 10.1016/j.tube.2024.102519. View

10.

Pasipanodya J, Ogbonna D, Deshpande D, Srivastava S, Gumbo T . Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease. J Antimicrob Chemother. 2017; 72(suppl_2):i3-i19. DOI: 10.1093/jac/dkx311. View

11.

Ruth M, Magombedze G, Gumbo T, Bendet P, Sangen J, Zweijpfenning S . Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. J Antimicrob Chemother. 2019; 74(7):1952-1961. DOI: 10.1093/jac/dkz143. View